Cibus, INC 10-Q quarterly reports

Cibus Inc. reported a 63% increase in Q1 2026 revenue to $1.7 million, driven by collaboration agreements, while net losses narrowed significantly due to cost reductions and a prior year goodwill impairment.

Cibus, Inc. reported reduced net losses and increased cash reserves for the nine months ended September 30, 2025, driven by cost-cutting and a sharpened focus on its Rice weed management traits.

Cibus, Inc. reported increased revenue and reduced operating cash burn in Q2 2025, driven by strategic streamlining and capital raises, despite a significant net loss and goodwill impairment.

Cibus Inc. announced its Q1 2025 financial results, showcasing advancements in its RTDS technology and regulatory approvals, while also reporting a net loss of $49.4 million and expressing substantial doubt about its ability to continue as a going concern.

Cibus Inc. reported a net loss of $201.5 million for the third quarter of 2024, including a significant goodwill impairment, and announced a strategic realignment to focus on commercialization.

Cibus Inc. announced its second quarter 2024 results, showcasing advancements in its trait development pipeline and commercialization efforts, alongside ongoing financial challenges.

Cibus Inc. reported a net loss of $27.0 million for the first quarter of 2024, while making significant strides in its gene editing technology and commercial partnerships.